Eluxadoline is approved by the Food and Drug Administration for the treatment of adults with irritable bowel syndrome with diarrhea (IBS-D). Eluxadoline is a locally acting mixed m-opiod and k-opioid receptor agonist and d-opioid receptor antagonist. The abuse potential of eluxadoline was evaluated as part of the Phase 2 and 3 clinical trials assessing the efficacy, safety, and tolerability of the drug.
METHODS:
One Phase 2 (IBS-2001) and two Phase 3 (IBS-3001 and IBS-3002) randomized controlled trials enrolled patients meeting Rome III criteria for IBS-D. Patients received oral twice-daily doubleblind treatment with eluxadoline or placebo for 12, 26, or 52 weeks. The primary end point of these studies was the proportion of patients who had a composite response of decrease in abdominal pain and improvement in stool consistency on the same day for at least 50% of days. Safety data were pooled, and specific adverse event terms potentially related to abuse were assessed descriptively. Adverse events reported during a 2-week post-treatment period (IBS-3001) and a 4-week single-blind washout period (IBS-3002) were assessed for signs of opioid withdrawal. Potential withdrawal effects were assessed by using the Subjective Opiate Withdrawal Scale.
RESULTS:
Overall, 807 and 1032 patients received 1 or more doses of eluxadoline (75 or 100 mg, respectively), and 975 patients received placebo. The overall incidence of adverse events potentially related to abuse did not differ significantly among the groups given placebo, eluxadoline 75 mg, or eluxadoline 100 mg (2.8%, 2.7%, and 4.3%, respectively). The most common adverse events potentially related to abuse were anxiety and somnolence, which occurred in less than 2% of patients in each group. Median overall Subjective Opiate Withdrawal Scale scores did not differ significantly among the groups given placebo, eluxadoline 75 mg, or eluxadoline 100 mg (3.0, 2.0, and 3.0, respectively).
CONCLUSIONS:
In an analysis of data from Phase 2 and Phase 3 trials of eluxadoline (75 or 100 mg) for patients with IBS-D, data revealed no signs of abuse potential for eluxadoline. ClinicalTrials.gov numbers: NCT01130272, NCT01553591, NCT01553747.
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I rritable bowel syndrome (IBS) is a common diagnosis in gastroenterology practices and one of the most frequent in the primary care setting. 1 Irritable bowel syndrome with diarrhea (IBS-D), one of the major subtypes of IBS, is a chronic gastrointestinal (GI) disorder characterized by recurring abdominal pain, bloating, and loose/frequent stools in the absence of structural, inflammatory, or biochemical abnormalities. IBS-D has a considerable impact on patient quality of life and is associated with a considerable burden on health care systems. 2, 3 (FDA) for adult patients with IBS-D. In Phase 3 trials, eluxadoline was well-tolerated and met the primary end point of achieving simultaneous improvement in both abdominal pain and stool consistency on 50% of days. 4 Eluxadoline also demonstrated statistically significant improvements in other IBS-related symptoms, including stool frequency and urgency. 4 Eluxadoline is a locally acting mixed m-opioid receptor (OR) and kOR agonist and dOR antagonist. Although its precise mode of action is complex, eluxadoline exerts its effects via ORs in the enteric circuitry of the GI tract, where they are known to play a role in regulating GI function. 5 ORs are G-protein-coupled receptors and are distributed widely throughout the GI tract. 6 Within the GI tract, ORs are found in smooth muscle cells and at the terminal of sympathetic and sensory peripheral neurons and act by affecting neuronal excitability via interaction with various neurotransmitters. 5 ORs play a major role in the regulation of GI transit and in the transport of fluids and electrolytes. 5 The main effects of OR agonists in the GI tract are reduced peristalsis, delayed gastric emptying, and the promotion of water and electrolyte absorption. 7, 8 Although mOR activation effects on GI motility and secretion have been most extensively studied, other receptor subtypes are also expressed peripherally. Antagonism of dOR has been shown to functionally counteract the inhibiting effects of mOR agonists on ileal contractions and to increase mORmediated central analgesia, [9] [10] [11] whereas agonism of kORs has been shown to attenuate visceral nociception as well as exert anti-inflammatory effects in the GI tract. 5, 12 ORs are also widely expressed in the central nervous system, and the analgesic effects of centrally acting OR agonists are well-established. The euphoric and addictive properties of centrally acting opioids are equally wellestablished, with recreational use and abuse of opioids dating back more than 1000 years. 13 The central effects of opioids involve multiple brain regions; in particular, activation of mORs in the mesolimbic reward system causes dopamine release and the resultant feelings of pleasure and reinforcement that contribute to abuse. 14 The repeated use of centrally acting opioids is also associated with tolerance, physical dependence, and withdrawal after abrupt discontinuation. In addition to concerns regarding abuse potential, classic mOR-acting drugs carry a high risk of severe respiratory depression and overdose, which are also important considerations for new opioid medications.
Loperamide, a commonly used mOR agonist available as an over-the-counter antidiarrheal agent, is not associated with abuse potential or serious risk of respiratory depression, 15 ,16 except in extremely rare cases when misused at supratherapeutic doses. 17 Importantly, systemic absorption of eluxadoline after oral administration is minimal. In healthy volunteers, the maximum plasma concentration of eluxadoline 100 mg administered orally was approximately 2-4 ng/mL, and the area under the curve was 12-22 ng.h/mL. 18 In addition, eluxadoline has approximately linear pharmacokinetics, with no accumulation on repeated twice-daily (BID) dosing. 18 On the basis of the low bioavailability of eluxadoline, which is similar to that observed for loperamide, one would expect eluxadoline to be associated with a similar lack of abuse potential or risk of respiratory depression. However, it is important to definitively establish the abuse potential of eluxadoline when used in the treatment of patients with IBS-D. Thus, specific data relating to abuse potential were recorded during the clinical trial program of eluxadoline.
Methods

Overview of Clinical Trials
IBS-2001, IBS-3001, and IBS-3002 (ClinicalTrial.gov identifiers:
NCT01130272, NCT01553591, and NCT01553747, respectively) were randomized, doubleblind, multicenter, placebo-controlled trials. Patients were randomized to receive eluxadoline or placebo BID for 12, 52, and 26 weeks, respectively. In IBS-2001, patients received eluxadoline (5, 25, 100, or 200 mg) or placebo BID. In IBS-3001 and IBS-3002, patients received eluxadoline (75 or 100 mg) or placebo BID.
The trials included male and female adults with a diagnosis of IBS-D according to Rome III criteria, 19 with minimal thresholds of symptom intensity for both worst abdominal pain and stool consistency. Patients with a history of inflammatory bowel disease, celiac disease, or intestinal obstruction or evidence of significant hepatic, vascular, or renal disease were excluded. Patients with current (defined as within 14 days of randomization) or expected use of any opioid-containing agent were also excluded. The full design and primary results of these studies have previously been reported. 4, 20 Authors had access to the study data and reviewed and approved the final manuscript.
Data Pooling
Because the study designs were very similar, safety data from these 3 studies were pooled for the placebo, eluxadoline 75 mg, and eluxadoline 100 mg treatment groups.
Assessment of Adverse Events Potentially Related to Abuse During Active Treatment Period
Adverse events (AEs) potentially related to abuse that occurred while on treatment were identified and summarized according to 2 separate sets of search terms. Initially, a comprehensive set of preferred terms was derived from the Medical Dictionary for Regulatory Activities based on the FDA draft Guidance for Industry, Assessment of Abuse Potential of Drugs 21 and a public presentation by FDA Controlled Substance Staff, 22 as well as input from independent medical experts. These preferred terms encompass euphoriarelated terms as well as terms relating to impaired attention, cognition, and mood, which are often associated with drugs of abuse (Supplementary Table 1 ).
Subsequently, a separate summary of AE terms was also assessed, which was based on an updated set of preferred terms proposed by members of the FDA Controlled Substance Staff 23 (Supplementary Table 2 ).
Assessment of Adverse Events Potentially Related to Withdrawal During Post-treatment Period
At the completion of each Phase 3 trial, patients who completed the treatment period entered a posttreatment assessment period, and AEs potentially indicative of opioid withdrawal occurring during this period were identified by the authors and summarized. In IBS-3001, there was a 2-week post-treatment followup for patients who completed the study (weeks 52-54). In IBS-3002, there was a 4-week, single-blind washout period (weeks 26-30), during which all patients received placebo. Because of these differences in methodology, data on AEs occurring during the posttreatment periods are presented separately for each Phase 3 study.
Subjective Opioid Withdrawal Scale
The Subjective Opioid Withdrawal Scale (SOWS) 24 was used in the Phase 3 studies to screen for any potential withdrawal effects after discontinuation of eluxadoline. It comprises questions relating to 16 withdrawal symptoms (Supplementary Table 3) , each rated on a scale of 0-4 (0, not at all; 1, a little; 2, moderately; 3, quite a bit; and 4, extremely). The total SOWS score ranges from 0 to 64, with higher scores indicating more severe withdrawal symptoms. In IBS-3001, patients were asked to complete the SOWS after discontinuation of treatment, either at completion of the trial (week 52) or as soon as possible after early discontinuation of study treatment. In IBS-3002, patients who discontinued the study before completion of the double-blind period were asked to complete the SOWS as soon as possible after early discontinuation of study treatment; however, to avoid jeopardizing study blinding, patients who continued into the 4-week single-blind placebo washout period were not asked to complete the SOWS at either initiation or completion of the 4-week placebo washout period. SOWS data were analyzed separately on the basis of time of collection relative to last dose of treatment (ie, 0, 1, 2, 3, and >3 days after treatment discontinuation).
Statistical Analysis
Safety end points were summarized by treatment group by using descriptive statistics. For AEs occurring during active treatment, the pooled safety analysis set comprised all patients who received 1 dose of study drug. For AEs occurring during the post-treatment periods, only those patients who completed the preceding treatment period and entered the post-treatment assessment were included. The SOWS score was analyzed by using an analysis of variance and the least squares mean difference, and the associated standard error, 95% confidence interval, and P values were calculated for each pair-wise comparison of active treatments (eluxadoline 75 mg or 100 mg) versus placebo.
Results
Patient Disposition and Multiple Randomizations
A total of 3235 patients were enrolled across the 3 studies. Of these, 2776 patients were randomized to receive placebo (n ¼ 981), eluxadoline 75 mg (n ¼ 810), or eluxadoline 100 mg (n ¼ 985). A total of 53 patients in IBS-3001 and 25 patients in IBS-3002 were affected by a treatment misallocation (at the week 18 and week 26 visits, respectively) because of an interactive voice response system error that was subsequently corrected. In addition, 10 patients were randomized into >1 studies, and a total of 11 patients were randomized more than once into a single study. For any patients affected by the treatment misallocation, randomized into more than 1 study, or randomized more than once into a single study, all available data were included and summarized according to the treatment actually received. Thus, the pooled safety analysis set comprised placebo (n ¼ 975), eluxadoline 75 mg (n ¼ 807), and eluxadoline 100 mg (n ¼ 1032).
Patient Demographics and Baseline Characteristics
The mean age was similar across all treatment groups, and approximately two-thirds of patients in each treatment group were female (Table 1) . Other baseline characteristics were also balanced across the treatment groups (Table 1) .
Adverse Events Potentially Related to Abuse During Active Treatment Period Based on Initial Set of Adverse Event Terms
The overall incidence of any AE potentially related to abuse was similar across the placebo, eluxadoline 75 mg, and eluxadoline 100 mg treatment groups (8.1%, 7.9%, and 9.6%, respectively). The most common of these AEs in all groups were dizziness and fatigue ( Table 2 ). All other AEs potentially related to abuse occurred in <2% of patients; incidence was comparable between the placebo and eluxadoline treatment groups ( Table 2 ). The incidence of these AEs was also similar across treatment groups when accounting for age, gender, race, and body mass index (Supplementary Tables 4-7) . 
Adverse Events Potentially Related to Abuse During Active Treatment Period Based on Updated Set of Adverse Event Terms
On the basis of the updated set of AE terms, the overall incidence of any AE potentially related to abuse remained similar across the placebo, eluxadoline 75 mg, and eluxadoline 100 mg treatment groups (2.8%, 2.7%, and 4.3%, respectively; Table 3 ). The most common of these AEs were anxiety and somnolence, both of which occurred in <2% of patients in each treatment group.
Euphoric mood was reported by 2 patients (0.2%), both of whom received eluxadoline 100 mg. These events occurred 1 and 3 days after the first dose of eluxadoline, respectively, and resolved without intervention or discontinuation of the study drug. Similarly, a feeling of drunkenness was reported by 2 patients receiving eluxadoline (1 receiving 75 mg and 1 receiving 100 mg; total of 0.1% for both arms combined). In both cases, the events were reported after the first dose of eluxadoline and resolved without intervention or discontinuation of eluxadoline.
Adverse Events Potentially Related to Withdrawal During Post-treatment Period
In patients who completed the entire 52 weeks of treatment in IBS-3001, the incidence of any AE during the subsequent 2-week post-treatment period was similar across treatment groups: 6.3%, 6.6%, and 7.0% for the placebo, eluxadoline 75 mg, and eluxadoline 100 mg groups, respectively. None of the AEs experienced during this period were serious. Of those potentially associated with opiate withdrawal, diarrhea and nausea each occurred in 1 patient receiving eluxadoline 75 mg and 1 patient receiving eluxadoline 100 mg, whereas abdominal pain occurred in 1 patient receiving eluxadoline 100 mg (Table 4) .
Similar to IBS-3001, the incidence of any AE was comparable across treatment groups during the 4-week single-blind washout period of IBS-3002 in patients who completed 26 weeks of treatment (placebo, 8.1%; eluxadoline 75 mg, 8.9%; eluxadoline 100 mg, 9.1%). During this period, upper abdominal pain was experienced by 2 patients (1 patient [0.4%] each who had received 75 mg eluxadoline or placebo in the doubleblind treatment period), and diarrhea was experienced by 1 patient (0.4%) who had received eluxadoline 100 mg in the double-blind treatment period (Table 4 ). In addition, no rebound worsening of IBS-D symptoms was reported during this period on the basis of patients' daily diary entries for their IBS symptoms. 4 Subjective Opiate Withdrawal Scale SOWS scores were generally low and similar across the placebo, eluxadoline 75 mg, and eluxadoline 100 mg treatment groups at 0, 1, 2, 3, and >3 days after treatment discontinuation (Figure 1 ). In addition, a statistical analysis of variance showed there were no significant differences between active treatment and placebo for overall SOWS scores or SOWS scores over time (Table 5) . pharmacologic properties of eluxadoline as an OR agonist/antagonist make it important to establish its abuse potential (or absence thereof). During clinical trials using FDA-approved doses, there was no convincing evidence that eluxadoline exhibited abuse potential, dependence potential, or opioidwithdrawal potential. AEs that were considered to be potentially related to abuse potential were uncommon and occurred with similar incidence across the placebo and eluxadoline groups. Known side effects of opiate use, such as feelings of drunkenness, euphoria, or sedation, each occurred in 3 eluxadoline-treated patients (0.2%). These events were not serious, resolved without intervention or discontinuation of the study drug, and were not associated with any other central nervous system events.
By using 2 different definitions of AEs potentially related to abuse, a slightly higher overall AE rate was noted comparing eluxadoline 100 mg with placebo (9.6% vs 8.1% and 4.3% vs 2.8%, respectively), whereas the rates in the eluxadoline 75 mg group were lower than placebo by both definitions. Some rare events commonly associated with opiates (drunkenness, euphoria, sedation; all 0.2%) were reported only in the treatment arms. However, caution should be exercised in the interpretation of these overall rates. First, there was no difference in overall rates comparing the eluxadoline 75 mg dose with placebo, and second, some events occurred exclusively in the placebo arm (agitation, anhedonia, depressed mood, emotional distress, memory impairment, mental status change, and nightmares). In addition, in the updated set of defined AEs, with the exception of anxiety (1.9%) and somnolence (1.1%), rates for all other events in more than 1000 patients receiving eluxadoline 100 mg were 0.3%. Notably, a single recording of a suicide attempt (6 tablets of Tylenol PM) occurred in the eluxadoline 100 mg group in a 24-yearold woman who was experiencing marital discord; after temporarily discontinuing the study drug for 3 days, the patient resumed therapy for an additional 3 months without further suicidal ideation.
There was also no evidence of opioid withdrawal after discontinuation of eluxadoline. AEs such as nausea and diarrhea were extremely uncommon after cessation of eluxadoline treatment. Median SOWS scores in the Phase 3 studies were consistent across placebo and eluxadoline groups and were extremely low, further indicating that eluxadoline cessation was not associated with opioid withdrawal. The observed median scores of 2 and 3 in the eluxadoline treatment groups were well below the score thought to reflect even mild opioid withdrawal discomfort. 25 In addition, median SOWS scores remained low and consistent across treatment groups when analyzed by time from treatment cessation, and no significant differences in SOWS scores between eluxadoline-treated patients and those who received placebo were observed overall or at any of the time points assessed. The isolated finding that the SOWS score for placebo was trending toward more withdrawal symptoms than the active arms on day 0 after discontinuation is considered an anomaly. Overall, the findings herein are consistent with the known low bioavailability of eluxadoline after oral administration and are in keeping with the experience with loperamide, an over-the-counter mOR agonist with extremely low systemic absorption. 15, 16 During the eluxadoline clinical trial program, there was no evidence of drug diversion or intentional drug abuse with eluxadoline, suggesting the 21 multiple randomizations identified did not reflect drug-seeking behavior. The issue of multiple enrollments is a wellestablished problem in the conduct of clinical trials, which is thought primarily to reflect so-called professional patients who learn how to pass the screening test based on the trial in question and enroll in several trials to receive financial incentives offered or for the "social reward" obtained through the attention the volunteer receives. 26 This is particularly plausible for IBS trials because there is no verifiable biomarker of IBS-D that can be used to confirm eligibility. Patients may also attempt to enroll multiple times to avail themselves of free health care visits and to try to ensure they are receiving the active treatment in a placebo-controlled study.
These clinical trials reflect the use of eluxadoline at approved doses and via the appropriate oral route of administration; hence the data are limited by the lack of any supratherapeutic doses or alternative routes of administration. Studies addressing both of these scenarios have been conducted, including eluxadoline ingested orally at doses up to 1000 mg in nondependent recreational opioid users and eluxadoline ingested intranasally. 27, 28 In these studies, eluxadoline produced both positive and negative subjective responses. The positive subjective responses elicited by eluxadoline were significantly less than those produced by oxycodone, and the small but significant effects on negative measures such as "drug disliking" and "bad drug effects" are likely to limit any abuse liability of eluxadoline. 27, 28 Exposure of eluxadoline by alternative routes of administration, such as injection, insufflation, or smoking, is expected to be severely limited in practice by the low tamperability and low extractability of eluxadoline tablets.
Although it cannot be concluded that eluxadoline is completely devoid of abuse potential, the current findings support that in the real-world setting, the anticipated potential for abuse of eluxadoline is extremely low. This is supported by the Drug Enforcement Agency decision to classify eluxadoline as a Schedule IV substance under the Controlled Substances Act. The Drug Enforcement Agency classifies drugs into 5 distinct categories (Schedules I-V), with Schedule I drugs being those considered to have the highest potential for abuse and Schedule V the lowest. The classification of schedule IV, which is defined as drugs with a low potential for abuse and low risk of dependence, therefore reflects the minimal abuse potential of eluxadoline, especially compared with other opioids such as oxycodone, which is a Schedule II drug.
In addition to the limited abuse potential, evidence suggests a favorable safety profile for eluxadoline with respect to risk of respiratory depression and overdose, which are often associated with opioids. A single case of respiratory depression was reported during eluxadoline clinical development; however, the patient, who received eluxadoline 100 mg, had several confounding factors predisposing them to respiratory depression including obesity, heavy smoking, and concomitant use of other central nervous system-active drugs. There were no known instances of overdose with eluxadoline during the clinical development program.
In summary, because of the low systemic absorption of eluxadoline and on the basis of these data from clinical trials, eluxadoline is expected to carry a very low risk of abuse potential or dependence liability when used in the treatment of IBS-D at the FDA-approved doses. In addition, evidence supports the view that there is no need for consideration of dose tapering when eluxadoline is discontinued. 
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